Breast cancer remains one of the most significant public health challenges affecting women worldwide. Improving prevention and treatment, strengthening international scientific collaboration, and promoting the global exchange of clinical knowledge are shared priorities across the oncology community.During the 23rd World Congress on Breast Healthcare, Oncology Frontier spoke with Professor Carole Mathelin, President of the Senologic International Society (SIS) and President of the French National Academy of Surgery, about the growing partnership between SIS and the Chinese Anti-Cancer Association (CACA) and how international collaboration can help advance breast health worldwide.
Oncology Frontier: Could you tell us about the collaboration between SIS and CACA, and how this partnership can contribute to improving breast cancer awareness and clinical care worldwide?
Professor Carole Mathelin:
SIS is a long-established scientific society, and this year marks an important milestone—our 50th anniversary. We warmly invite colleagues from around the world to join us in celebrating this occasion.
As an international federation representing hundreds of professional societies, SIS brings together hospitals, clinical institutions, patient advocacy organizations, and individual members. Our mission has always been to provide the best possible care for patients with breast cancer.
Collaboration between scientific organizations is essential for advancing global breast health. SIS and CACA can work together by participating in webinars, international congresses, and regional scientific meetings, allowing the rapid exchange of new research findings and clinical experience. We also have opportunities to jointly develop educational resources covering breast cancer prevention, screening, diagnosis, and treatment, helping disseminate evidence-based knowledge worldwide.
SIS has also established a regular communication mechanism through Executive Board meetings held every two months, where we discuss current challenges and future priorities in breast cancer care. This provides a stable platform for continued collaboration, and I believe there is tremendous potential for further partnership between SIS and CACA.
Oncology Frontier: How do you personally view the future of collaboration with CACA?
Professor Carole Mathelin:
Our collaboration with CACA is extremely important to SIS.
China has become a global leader in several key areas, including the application of artificial intelligence, algorithm development, basic research into breast cancer biology, and clinical research. In addition, China has an outstanding research community that produces both a large volume of scientific publications and research of internationally recognized quality.
For these reasons, strengthening our collaboration with CACA is a natural and important step toward fulfilling the mission of SIS. By working together more closely, we can accelerate scientific progress and make meaningful contributions to improving breast health around the world.
Professor
Carole Mathelin
President, Senologic International Society (SIS)
President, French National Academy of Surgery
